Skip to content
2000
image of Network Pharmacology Approach to Predict the Mechanisms of Loganin on Alzheimer Disease via Galectin-3 Inhibition

Abstract

Introduction

Alzheimer's disease (AD) is the world's leading cause of neurological dysfunction, cognitive decline, and neuronal loss in the elderly. The deposition of beta amyloid (Aβ)-containing plaques, and the formation of tau-containing neurofibrillary tangles (NFTs), along with extensive neuroinflammation, are the events that characterize the pathogenesis of AD. The management of this disease remains a significant global challenge, as researchers continuously explore innovative treatment approaches, including the investigation of natural products. Loganin is one of the best-known iridoid glycosides. It is named for the Loganiaceae, having first been isolated from the seeds of a member of that plant family, namely those of Strychnos nux-vomica. It has been reported to have anti-inflammatory effects in various disease models such as Parkinson's disease and acute pancreatitis. Recent investigations have uncovered the preventive effects against Alzheimer's disease and its associated complications. This study focused on the therapeutic potential of loganin in the management of Alzheimer's disease.

Methods

The potential molecular target of loganin was identified using the SwissTarget Prediction platform, and the disease target of Alzheimer's disease was identified using the GeneCards database. STRING, Cytoscape, and CB-Dock 2 were used to construct the network pharmacology.

Results

The Venn diagram assisted in shortlisting the top 10 genes from 91 overlapping genes, using Cytoscape, namely ALB, TNF, IL6, EGFR, SRC, IL2, HSP90AA1, MMP2, LGALS3, and REN, which was estimated by the CytoHubba plug-in. The molecular binding score of loganin was determined by using CB-Dock 2 and showed the highest binding energy of -8.7 kcal/mol for the LGALS3 (Galectin-3) protein compared with other proteins.

Discussion

The integration of network pharmacology with molecular docking thus provides a robust foundation for understanding the multi-target action of loganin, as it regulates the proteins involved in pathways associated with Alzheimer's disease via Galectin-3, supporting the development of natural therapies for the efficient management of Alzheimer's disease.

Conclusion

Combined with a healthy lifestyle, such natural interventions may offer a complementary strategy to help delay or mitigate Alzheimer’s disease progression.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdth/10.2174/0115748855404595250908114801
2025-09-30
2025-11-06

  • From This Site

    /content/journals/cdth/10.2174/0115748855404595250908114801
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Singh M.K. Shin Y. Ju S. Han S. Kim S.S. Kang I. Comprehensive overview of Alzheimer’s disease: Etiological insights and degradation strategies. Int. J. Mol. Sci. 2024 25 13 6901 10.3390/ijms25136901 39000011
    [Google Scholar]
  2. Haddad H.W. Malone G.W. Comardelle N.J. Degueure A.E. Kaye A.M. Kaye A.D. Aducanumab, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer’s disease: A comprehensive review. Health Psychol. Res. 2022 10 1 31925 10.52965/001c.31925 35928986
    [Google Scholar]
  3. Kinney J.W. Bemiller S.M. Murtishaw A.S. Leisgang A.M. Salazar A.M. Lamb B.T. Inflammation as a central mechanism in Alzheimer’s disease. Alzheimers Dement. 2018 4 1 575 590 10.1016/j.trci.2018.06.014 30406177
    [Google Scholar]
  4. Bronzuoli M.R. Iacomino A. Steardo L. Scuderi C. Targeting neuroinflammation in Alzheimer’s disease. J. Inflamm. Res. 2016 9 199 208 10.2147/JIR.S86958 27843334
    [Google Scholar]
  5. Moutinho M. Codocedo J.F. Puntambekar S.S. Landreth G.E. Nuclear receptors as therapeutic targets for neurodegenerative diseases: Lost in translation. Annu. Rev. Pharmacol. Toxicol. 2019 59 1 237 261 10.1146/annurev‑pharmtox‑010818‑021807 30208281
    [Google Scholar]
  6. Lunn J.S. Sakowski S.A. Hur J. Feldman E.L. Stem cell technology for neurodegenerative diseases. Ann. Neurol. 2011 70 3 353 361 10.1002/ana.22487 21905078
    [Google Scholar]
  7. Hampel H. O’Bryant S.E. Durrleman S. A precision medicine initiative for Alzheimer’s disease: The road ahead to biomarker-guided integrative disease modeling. Climacteric 2017 20 2 107 118 10.1080/13697137.2017.1287866 28286989
    [Google Scholar]
  8. Woźniak K. Gardian-Baj M. Jung M. Alzheimer’s disease - A comprehensive review. J. Educ. Health Sport 2024 56 195 209 10.12775/JEHS.2024.56.013
    [Google Scholar]
  9. Najm R. Jones E.A. Huang Y. Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease. Mol. Neurodegener. 2019 14 1 24 10.1186/s13024‑019‑0324‑6 31186040
    [Google Scholar]
  10. Luo J. Chen S. Zhang N. Gao S. Piao C. Investigation of the mechanism of action of simiao pill against gout using network pharmacology and experimental validation. J. Herb. Med. 2023 41 100693 10.1016/j.hermed.2023.100693
    [Google Scholar]
  11. Liu Z.W. Luo Z.H. Meng Q.Q. Zhong P.C. Hu Y.J. Shen X.L. Network pharmacology-based investigation on the mechanisms of action of Morinda officinalis How. in the treatment of osteoporosis. Comput. Biol. Med. 2020 127 104074 10.1016/j.compbiomed.2020.104074 33126122
    [Google Scholar]
  12. Shi S. Tian X. Gong Y. Pivotal role of JNK protein in the therapeutic efficacy of parthenolide against breast cancer: Novel and comprehensive evidences from network pharmacology, single-cell RNA sequencing and metabolomics. Int. J. Biol. Macromol. 2024 279 Pt 3 135209 10.1016/j.ijbiomac.2024.135209 39244135
    [Google Scholar]
  13. Chowdhury H.U. Adnan M. Oh K.K. Cho D.H. Decrypting molecular mechanism insight of Phyllanthus emblica L. fruit in the treatment of type 2 diabetes mellitus by network pharmacology. Phytomed Plus 2021 1 4 100144 10.1016/j.phyplu.2021.100144
    [Google Scholar]
  14. Chen B. Huang X. Zhu F. Integrating network pharmacology and experimental verification to study the mechanism of Polygonum hydropiper total flavonoids against stress-induced gastric mucosal damage. Heliyon 2024 10 19 e38629 10.1016/j.heliyon.2024.e38629 39403481
    [Google Scholar]
  15. Gayathiri E. Prakash P. Chaudhari S.Y. Interaction of molecular mechanisms of plant-derived metabolites in Type 2 diabetes mellitus: A network pharmacology, docking and molecular dynamics approach on AKT1 kinase. Energy Nexus 2025 17 100351 10.1016/j.nexus.2024.100351
    [Google Scholar]
  16. Tang D. Chen M. Huang X. SRplot: A free online platform for data visualization and graphing. PLoS One 2023 18 11 e0294236 10.1371/journal.pone.0294236 37943830
    [Google Scholar]
  17. Ge S.X. Jung D. Yao R. Shiny G.O. A graphical gene-set enrichment tool for animals and plants. Bioinformatics 2020 36 8 2628 2629 10.1093/bioinformatics/btz931 31882993
    [Google Scholar]
  18. Jesudass J.S. Sivaprakasam B. Kulanthaivel S.R. Computational identification of bioactive molecules from Caralluma stalagmifera L. as potential VEGFR2 inhibitors for endometriosis treatment. J. Pharm. Innov. 2025 20 1 18 10.1007/s12247‑024‑09894‑y
    [Google Scholar]
  19. Heneka M.T. Carson M.J. Khoury J.E. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015 14 4 388 405 10.1016/S1474‑4422(15)70016‑5 25792098
    [Google Scholar]
  20. Hickman S.E. Kingery N.D. Ohsumi T.K. The microglial sensome revealed by direct RNA sequencing. Nat. Neurosci. 2013 16 12 1896 1905 10.1038/nn.3554 24162652
    [Google Scholar]
  21. Boza-Serrano A. Ruiz R. Sanchez-Varo R. Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimer’s disease. Acta Neuropathol. 2019 138 2 251 273 10.1007/s00401‑019‑02013‑z 31006066
    [Google Scholar]
  22. Wang X. Zhang S. Lin F. Chu W. Yue S. Elevated galectin-3 levels in the serum of patients with Alzheimer’s disease. Am. J. Alzheimers Dis. Other Demen. 2015 30 8 729 732 10.1177/1533317513495107 23823143
    [Google Scholar]
  23. Boza-Serrano A. Vrillon A. Minta K. Galectin-3 is elevated in CSF and is associated with Aβ deposits and tau aggregates in brain tissue in Alzheimer’s disease. Acta Neuropathol. 2022 144 5 843 859 10.1007/s00401‑022‑02469‑6 35895141
    [Google Scholar]
  24. Soares L.C. Al-Dalahmah O. Hillis J. Novel galectin-3 roles in neurogenesis, inflammation and neurological diseases. Cells 2021 10 11 3047 10.3390/cells10113047 34831271
    [Google Scholar]
  25. Tan Y. Zheng Y. Xu D. Sun Z. Yang H. Yin Q. Galectin-3: A key player in microglia-mediated neuroinflammation and Alzheimer’s disease. Cell Biosci. 2021 11 1 78 10.1186/s13578‑021‑00592‑7 33906678
    [Google Scholar]
  26. Tao C.C. Cheng K.M. Ma Y.L. Galectin-3 promotes Aβ oligomerization and Aβ toxicity in a mouse model of Alzheimer’s disease. Cell Death Differ. 2020 27 1 192 209 10.1038/s41418‑019‑0348‑z 31127200
    [Google Scholar]
  27. García-Revilla J. Boza-Serrano A. Espinosa-Oliva A.M. Galectin-3, a rising star in modulating microglia activation under conditions of neurodegeneration. Cell Death Dis. 2022 13 7 628 10.1038/s41419‑022‑05058‑3 35859075
    [Google Scholar]
  28. Srejovic I. Selakovic D. Jovicic N. Jakovljević V. Lukic M.L. Rosic G. Galectin-3: Roles in neurodevelopment, neuroinflammation, and behavior. Biomolecules 2020 10 5 798 10.3390/biom10050798 32455781
    [Google Scholar]
/content/journals/cdth/10.2174/0115748855404595250908114801
Loading
Network Pharmacology Approach to Predict the Mechanisms of Loganin on Alzheimer Disease via Galectin-3 Inhibition
Bentham Science Publishers ; https://doi.org/10.2174/0115748855404595250908114801
/content/journals/cdth/10.2174/0115748855404595250908114801
/content/journals/cdth/10.2174/0115748855404595250908114801
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: Alzheimer diseases ; pathogenesis ; gene ; Loganin ; protein

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test